首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >Solid dispersions of efonidipine hydrochloride ethanolate with improved physicochemical and pharmacokinetic properties prepared with microwave treatment
【24h】

Solid dispersions of efonidipine hydrochloride ethanolate with improved physicochemical and pharmacokinetic properties prepared with microwave treatment

机译:用微波处理制备的改善物理化学和药代动力学性质的盐酸盐酸盐酸盐乙酸盐的固体分散体

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Drug absorption into the body is known to be greatly affected by the solubility of the drug itself. The active pharmaceutical ingredient efonidipine hydrochloride ethanolate (N2-105) is a novel 1,4-dihydropyridine calcium antagonist that has a very low solubility in water. It is classified as a poorly soluble drug, and improvements in its solubility and higher bioavailability with oral administration are needed. In this study, employing microwave technology as a new means to improve solubility, we established a method for preparing solid dispersions using hydroxypropyl methylcellulose acetate succinate as a polymeric carrier and urea as a third component. This effective method has a treatment time of several minutes (simple) and does not require the use of organic solvents (low environmental impact). The third component, urea, acts to lower the melting point of NZ-105, which promotes amorphization. This greatly improves the solubility compared with the microwave-treated product of NZ-105/FIPMC-AS binary system. The solid dispersion prepared with this method, in addition to evaluation in vitro, was tested in vivo using beagle dogs and shown to be effective from the eightfold improvement in absorption compared with NZ-105 alone based on the area under the curve. (C) 2016 Elsevier B.V. All rights reserved.
机译:已知药物吸收到体内的吸收受药物本身的溶解度的大大影响。活性药物成分盐酸盐酸盐乙醇酸酯(N2-105)是一种新的1,4-二氢吡啶钙拮抗剂,其在水中具有非常低的溶解度。将其被归类为可溶于可溶性药物,并且需要具有口服给药的溶解度和更高的生物利用度。在该研究中,采用微波技术作为提高溶解度的新方法,我们建立了使用羟丙基甲基纤维素乙酸酯酸琥珀酸作为聚合物载体和尿素作为第三组分的制备固体分散体的方法。这种有效方法具有几分钟的治疗时间(简单),不需要使用有机溶剂(低环境影响)。第三组分尿素尿素作用以降低NZ-105的熔点,促进非晶化。与NZ-105 / FIPMC-AS二元系统的微波处理产物相比,这大大改善了溶解度。除了在体外评价之外,用该方法制备的固体分散体在体内使用比猎犬犬进行测试,并显示与单独的NZ-105基于曲线下的区域相比,从吸收的八倍改善有效。 (c)2016年Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号